Depemokimab-Ulaa: uses, dosing, side effects & brands
Depemokimab-Ulaa is a medicine sold in the U.S. under one brand, for asthma. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Asthma
- Available as
- Injectable
- Sold as
- Exdensur
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How depemokimab-ulaa is dosed
From the FDA label for Exdensur (application BLA761458). Other depemokimab-ulaa products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
The recommended dosage is 100 mg administered once every 6 months by subcutaneous injection into the upper arm, thigh, or abdomen. ( 2.1 ) • EXDENSUR should be administered by a healthcare provider. ( 2.2 ) • See full prescribing information for preparation and administration instructions. ( 2.2 ) 2.1 Recommended Dosage The recommended dosage is 100 mg once every 6 months administered by subcutaneous injection into the upper arm, thigh, or abdomen avoiding 2 inches (5 cm) around the navel [see Dosage and Administration ( 2.2 )] . Missed Dose(s) If a dose is missed, administer the missed dose as soon as possible and resume the once every 6‑month injection schedule from the date of when the missed dose was given. 2.2 Preparation and Administration Instructions for EXDENSUR • EXDENSUR is for subcutaneous use only. • EXDENSUR should be administered by a healthcare provider. • Do not use EXDENSUR prefilled syringe if the security seal on the carton has been broken or if it has been dropped or damaged. Preparation Instructions 1. Remove the prefilled syringe from the refrigerator. Holding the middle of the prefilled syringe, take it out from the tray and allow it to sit at room temperature for 30 minutes prior to injection. Do not warm EXDENSUR injection in any other way. Do not remove the needle cap until you are ready to inject. Do not use the syringe if it has been left out of…
Depemokimab-Ulaa side effects
The following adverse reactions are discussed in greater detail in other sections of the labeling: • Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] . The most common adverse reactions (incidence ≥4%) are upper respiratory tract infection, allergic rhinitis, influenza, arthralgia, and pharyngitis. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact GlaxoSmithKline at 1-888-825-5249 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of EXDENSUR was based on a pooled safety population from 2 replicate, randomized, double‑blind, parallel‑group, placebo‑controlled, multicenter clinical trials (SWIFT‑1 and SWIFT‑2) of 52 weeks duration. The 2 trials included 762 adult and pediatric patients 12 years of age and older with asthma, who received either EXDENSUR 100 mg or placebo administered subcutaneously once every 6 months in addition to their existing background medications for asthma [see Clinical Studies ( 14 )] . A total of 475 patients received 2 doses of EXDENSUR 100 mg in these trials. Adverse reactions with EXDENSUR with incidence of ≥4% are shown in…
Who shouldn’t take depemokimab-ulaa
None. None. ( 4 )
Every depemokimab-ulaa product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Exdensur.
Related calculators
Frequently asked questions
What is depemokimab-ulaa?
Exdensur (Depemokimab-Ulaa) is a medication used to treat Asthma.
Can you take depemokimab-ulaa with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run depemokimab-ulaa against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does depemokimab-ulaa come in?
Across the brands we track, depemokimab-ulaa is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic depemokimab-ulaa?
We do not currently list a generic-labelled depemokimab-ulaa product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Depemokimab-Ulaa: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/depemokimab-ulaa
- MLA
- “Depemokimab-Ulaa: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/depemokimab-ulaa.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for depemokimab-ulaa on DailyMed (NIH) ↗.